Liposomal Irinotecan in First-Line Treatment of Metastatic Pancreatic Adenocarcinoma – The ASCO Post
On February 13, 2024, the U.S. Food and Drug Administration approved liposomal irinotecan (Onivyde) for use with oxaliplatin, fluorouracil, and leucovorin in the first-line treatment of metastatic pancreatic adenocarcinoma. 1 Approval was based on the open-label NAPOLI 3 trial (ClinicalTrials.gov identifier NCT04083235), in which 770 patients who had received no chemotherapy in the me tastatic setting were randomly assigned to receive the following treatments: NALIRIFOX: Liposomal irinotecan at 50 mg/m